Aeglea Cuts Majority of Staff Following Mixed Trial Results
Aeglea Cuts Majority of Staff Following Mixed Trial Results Published: Apr 12, 2023 - Original Story Wednesday, Aeglea Biotherapeutics announced it was reducing its headcount as part of a sweeping reorganization following mixed interim data from an ongoing Phase I/II study of its classical homocystinuria candidate pegtarviliase. As part of its strategic review, Aeglea is laying off all [...]